logo
Western Canada glaciers melting twice as fast as in previous decade, research says

Western Canada glaciers melting twice as fast as in previous decade, research says

CTV News25-06-2025
Robson Glacier is shown in this handout photo provided by the Hakai Institute. A research letter published in a peer-reviewed journal this week shows glaciers in Western Canada and the United States, excluding Alaska and Yukon, lost 12 per cent of their mass from 2021 to 2024, while the rate of loss increased twofold. THE CANADIAN PRESS/Handout — Hakai Institute
Researchers say some glaciers in Western Canada and the United States lost 12 per cent of their mass from 2021 to 2024, doubling melt rates compared to the previous decade in a continuation of a concerning global trend.
The research led by University of Northern British Columbia professor Brian Menounos says low snow accumulation over winter, early-season heat waves, and prolonged warm and dry spells were contributing factors.
It says impurities such as ash from severe wildfire seasons have also 'darkened' glaciers, causing them to absorb more heat and triggering a feedback loop that will lead to continued loss unless the ice is covered by fresh snow.
The study, published in the peer-reviewed journal Geophysical Research Letters this week, examined glaciers in Western Canada and the United States, excluding Alaska and Yukon, as well as Switzerland, where glaciers lost 13 per cent of their mass over the same period.
The research letter says glaciers in both regions lost mass twice as fast as they did between 2010 and 2020.
Menounos says climate change and its effects, including heat waves and changing snow patterns, are draining the 'bank account' of fresh water that glaciers contain.
'Doubling the amount of water that's lost from those glaciers, we're sort of stealing from the future,' says Menounos, the Canada Research Chair in glacier change.
'We are just pulling and pulling away and making that bank account closer to zero and perhaps even negative. We're not replenishing these glaciers,' he says.
The research letter published Wednesday follows a 2021 study published in the peer-reviewed journal Nature that found glaciers outside the Greenland and Antarctic ice sheets lost mass between 2010 and 2019 at double the rate they did in the first decade of this century. Menounos contributed to that study.
The latest research combined aerial surveys with ground-based observations of three glaciers in Western Canada, four glaciers in the United States and 20 in Switzerland.
The analysis shows that between 2021 and 2024, those glaciers experienced their highest rates of loss since monitoring began 60 years ago, Menounos says.
The study says that in Western Canada and the United States, black carbon doubled after about 2010, reaching the highest level of deposition in 2023 -- coinciding with a severe wildfire season across B.C. and Canada.
The study did not include specific data relating to wildfire ash on each glacier, but Menounos says any darker material will absorb more heat and enhance melting.
The researchers did zero in on the Haig Glacier in the Canadian Rockies, finding the low reflectivity of the ice contributed to 17 per cent of an unprecedented loss of mass in 2022 and 2023. Summer heat had the greatest effect, responsible for 46 per cent of the loss, the letter says.
Current modelling for glaciers often doesn't include wildfire ash and other processes that could accelerate rates of loss in the future, Menounos added.
'We think that wildfire will continue to play an important role and certainly we need better physical models to project how these glaciers are likely to change.'
Glaciers across the study area are projected to mostly disappear by the end of the century, even under moderate climate change scenarios. Only some of the largest glaciers and icefields are expected to exist beyond 2100, the research letter says.
Swiss glaciers represent about 55 per cent of the total volume of central European glaciers, and findings there may be applied across the Alps, the letter notes.
From 2000 to 2023, the letter says Earth's glaciers collectively lost mass at a rate of about 273 gigatonnes per year, accounting for about one-fifth of observed sea-level rise. One gigatonne represents one cubic kilometre of water, Menounos says.
'The way to perhaps bring some of the smallest glaciers back is, sometime in the future, with reduced greenhouse gas emissions,' he says.
'It's a global problem, but it does require input from all countries.'
This report by The Canadian Press was first published June 25, 2025.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Face to face with a perfectly preserved dinosaur that looks like it was alive yesterday
Face to face with a perfectly preserved dinosaur that looks like it was alive yesterday

CBC

timean hour ago

  • CBC

Face to face with a perfectly preserved dinosaur that looks like it was alive yesterday

Graham Duggan An accidental discovery of a 3D fossil reveals the dinosaur's mysterious death Parts of Alberta are libraries of Earth's history, treasure troves of fossils from animals that lived millions of years ago. But sometimes, an especially rare gem is found. In Dinosaur Cold Case, a documentary from The Nature of Things, we meet the remarkable dinosaur known as Borealopelta — preserved in eye-popping 3D. Paleontologists are solving the mystery of what killed it, how it came to rest at the bottom of a prehistoric sea and how it was preserved so perfectly. The accidental discovery of an incredible dinosaur In March 2011, Shawn Funk, a shovel operator at Suncor Energy's Millennium oilsands mine north of Fort McMurray, Alta., was digging away at a large bank when he inadvertently stumbled upon Alberta's oldest dinosaur fossil and one of the most well-preserved dinosaur fossils ever found. "Right away, we knew it was going to be something good," says Don Henderson, curator of dinosaurs at the Royal Tyrrell Museum in Drumheller, Alta. "But we had no idea how good it was going to be." After getting the fossil back to the museum, Don and his team set to work solving the 110-million-year-old mystery. The life and times of Borealopelta Six years after it was found, the mysterious dino was declared a new species to science and given a proper name: Borealopelta markmitchelli. " Borealopelta" means "shield of the North," and its species name is a nod to Mark Mitchell, the Royal Tyrrell Museum technician who spent 7,000 hours fighting for every millimetre while freeing the dinosaur from the rock it was found in. The approximately five-and-a-half-metre-long specimen was so perfectly preserved that researchers were able to stare into the face of a real dinosaur that lived during a time when North America was a very different place. Borealopelta was built like a tank and covered in thick armour, especially around its neck, indicating that it needed protection from predators. At its shoulders, a massive, 51-centimetre-long spike extended out on either side. At first, it was thought these weapons could have been used for fighting other Borealopeltas, but Victoria Arbour, curator of palaeontology at the Royal BC Museum, believes they could have been used for both love and war. "When you see something like a huge spike," says Arbour, "that could simultaneously be a signal to mates that you're in good health." Borealopelta's massive shoulder spikes could have acted like a bull's horns or an elephant's tusks, which are used in defense when necessary but are also an indicator of status and strength. Many of the fossilized armour plates possessed a keratin sheath (the same material as our fingernails) with a thin film that allowed researchers to guess at Borealopelta 's colour. "It was found that at least one component of Borealopelta 's colour was this reddish brown," says Caleb Brown, a curator at the Royal Tyrrell Museum. "The pigment seemed to be concentrated on the back of the animal and not the belly, and this is consistent with this idea of countershading." Countershading allows animals to blend with their environment and hide from keen-eyed predators. Although some researchers question whether the colouration was just an anomaly of fossilization, if Borealopelta, an almost 1,300-kilogram animal, did require camouflage, it must have had some terrifying predators indeed. The terrifying dinosaur of the day, 110 million years ago, was Acrocanthosaurus, a killing machine that ruled the Cretaceous long before more well-known predators like T. rex arrived on the scene. Could an attack from an Acrocanthosaurus have been the cause of Borealopelta 's death? In a simulated test, researchers found that Acrocanthosaurus's bite would have done some serious damage to Borealopelta, and it was likely one of its main predators. But this particular specimen was found in such pristine condition, with no signs of trauma, that it must have died another way... Dino's last meal may be the key to its mysterious death After studying the location the fossil was found, the team determined that Borealopelta likely came to rest, belly up, at the bottom of a prehistoric sea. In an extremely rare find, the stomach contents of Borealopelta were preserved along with its body, providing an important clue as to how it got there. Paleobotanist David Greenwood examined Borealopelta 's miraculously fossilized last meal and discovered twigs and ferns. Incredibly, the twigs appeared to be in mid-growth, indicating that they were eaten during the wet season, when extreme storms and flash floods would have been a real problem. On the coastal plains where Borealopelta lived, a rapid rise in water level could have caught it off guard — and Borealopelta was not built for swimming. Borealopelta is preserved in incredible detail If Borealopelta drowned in a torrent that swept it away, how did it come to rest upside down on the sea floor? Henderson and Brown went back to the records to see the position in which other armoured dinosaur fossils in Alberta were found, and discovered that about 70 per cent of these dinosaurs were also found on their backs. "As [ Borealopelta ] started to rot," Brown reasons, "gases built up within the body cavity." In the water, the rest was simple physics. "That bloated body, with the soft belly and dense back, causes it to flip over," says Henderson. "Its arms and legs [would have been] sticking up in the air." With its stiff limbs acting as sails, Borealopelta would have caught the wind and literally sailed out to sea, travelling a long way into open water. Then, says Henderson, "it goes pop … and it goes down like a stone." Borealopelta would have hit the sea floor with force, burying itself in sediment that was disturbed from the impact — key to the fossil's incredible preservation. Through a chemical reaction, this sediment would have formed a natural concrete, preserving the body within its own sarcophagus. Henderson and Brown suspect this is how Borealopelta was protected from immense pressure and decay. Safe within this natural time capsule, the nodosaur waited 110 million years until one fateful day, when a miner in Alberta came across a miraculous find and Borealopelta 's mysteries were unearthed.

Why biohacker Bryan Johnson wants to sell his anti-aging business to build a new religion
Why biohacker Bryan Johnson wants to sell his anti-aging business to build a new religion

National Post

time2 hours ago

  • National Post

Why biohacker Bryan Johnson wants to sell his anti-aging business to build a new religion

Tech entrepreneur and longevity crusader is thinking of ditching his 'pain-in-the-ass' anti-aging nutrition and supplements company to focus on his 'Don't Die' movement, a community of likeminded biohackers 'united in defeating all causes of human and planetary death.' Article content In a lengthy interview with Wired, the 47-year-old California multimillionaire said he is 'so close' to shutting down or selling Blueprint, a wellness company devoted to 'maximally slowing' aging and reversing aging that's already occurred. Article content Article content 'I've been talking to people about this. I don't need the money, and it's a pain-in-the-ass company,' Johnson told Wired's Katie Drummond. Article content Article content Johnson said Blueprint evolved from his own personal search for a clean, low-in-heavy-metals protein powder into a business venture that was just 'trying to do people a solid. The problem is now people see the business and give me less credibility on the philosophy side. I will not make that trade off … So yeah, I don't want it.' Article content The self-described most measured human on the planet, Johnson takes 40 odd vitamins and supplements daily as well as hundreds of daily measurements of his heart, liver, lungs, kidneys and other body organs so that they may 'speak for themselves what they need to be in their ideal state.' Article content In 2023, Johnson, his then 17-year-old son and Johnson's father participated in a multi-generational plasma exchange. Johnson received plasma from a litre of blood siphoned from his son at a Texas spa in the hope his son's blood would make him younger. Article content The plasma swap apparently had a null effect: In January, Johnson posted on X that he was no longer injecting his son's blood and had 'upgraded' to another controversial plasma protocol. Article content I am no longer injecting my son's blood. I've upgraded to something else: total plasma exchange. Steps: 1. Take out all blood from body 2. Separate plasma from blood 3. Replace plasma with 5% albumin & IVIG Here's my bag of plasma. Who wants it? 🧵 — Bryan Johnson (@bryan_johnson) January 28, 2025 Article content Johnson eats all the day's food before noon and sticks to a strict high-fibre, 'veggies and legumes,' no alcohol, no sugar diet that makes him feel sharper while avoiding 'post meal dead zones,' he's shared on X. Article content Last year, in a therapy dubbed 'Project Baby Face,' Johnson attempted to restore volume he's lost on his face from a calorie-reduced diet with fat injections in his temple, cheeks and chin. He didn't have enough of is own body fat so he used donor fat. It didn't go well: 'Immediately following the injections, my face began to blow up,' Johnson posted on Instagram. 'And then it got worse, and worse, and worse until I couldn't even see,' a severe allergic reaction. Article content What is Project Blueprint? Article content Johnson has explained how, In 2021, 'I endeavoured to figure out proximity to longevity escape velocity. How far away are we from one year of chronological time passing and one staying the same age biologically? I called this Project Blueprint.'

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

National Post

time4 hours ago

  • National Post

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Article content Article content CAMBRIDGE, Mass. — Enveric Biosciences (NASDAQ: ENVB) ('Enveric' or the 'Company'), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced a second Notice of Allowance from the United States Patent and Trademark Office (USPTO) for novel compounds within its EVM401 Series, expanding its intellectual property assets in the treatment of mental health disorders. Article content The allowed patent application, titled 'Substituted N-Propylamine Fused Heterocyclic Mescaline Derivatives,' covers a unique series of methylone-inspired compounds, which are structurally differentiated benzodioxole derivatives engineered as non-hallucinogenic modulators of neurotransmitters relevant for neuropsychiatric disorders. Article content 'With this second patent allowance for the EVM401 Series, Enveric continues to strengthen its position as a first-in-class developer of neuroplastogenic small-molecule therapeutics,' said Joseph Tucker, Ph.D., Director and CEO of Enveric. 'These patent-protected molecules are designed to capture the desirable neuroplasticity-promoting effects of methylone, while offering novel chemical structures that enable both strong IP protection and a potential path to repeat-dose outpatient care.' Article content Enveric's molecules share pharmacophoric elements with methylone, an MDMA analog recently associated with positive Phase 2 results for post-traumatic stress disorder (PTSD), but differ structurally in ways that render them patentable and proprietary. In contrast, methylone, a synthetic cathinone with structural limitations, has no available composition of matter patent exclusivity because its structure is in the public domain. Article content Enveric's differentiated benzodioxole analogs may offer similar therapeutic promise while potentially enabling a clearer regulatory and commercial path. The Company expects further preclinical testing will be required to evaluate safety, pharmacokinetics, and functional activity against PTSD and other psychiatric endpoints. Article content 'The expansion of the EVM401 Series reflects Enveric's commitment to developing a deep pipeline of next-generation, non-hallucinogenic neuroplastogens that align with the scalability and safety needs of modern mental health treatment,' added Dr. Tucker. 'We believe this patent further positions Enveric at the forefront of the development of a new wave of targeted, accessible neuroplastogenic small-molecule drugs' Article content About Enveric Biosciences Article content Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders. Leveraging its unique discovery and development Psybrary™ platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, Enveric seeks to develop a robust intellectual property portfolio of novel drug candidates. Enveric's lead molecule, EB-003, is a potential first-in-class neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other novel, patented Psybrary™ platform drug candidates to third-party licensees advancing non-competitive market strategies for patient care. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit Article content Forward-Looking Statements Article content This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as 'plans,' 'expects' or 'does not expect,' 'proposes,' 'budgets,' 'explores,' 'schedules,' 'seeks,' 'estimates,' 'forecasts,' 'intends,' 'anticipates' or 'does not anticipate,' or 'believes,' or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric's products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively. Article content A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric's filings with the Securities and Exchange Commission, including Enveric's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Article content Article content Article content Article content Contacts

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store